Whalesbook
Sun Pharmaceutical Industries announced strong financial results for the fourth quarter of fiscal year 2026, with consolidated net profit increasing by 26.2% year-on-year to Rs 2,714 crore. This growth was significantly boosted by robust sales in India and its expanding portfolio of innovative medicines.
India Business Drives Performance
The company's domestic formulations business was a key driver, achieving a 14.8% year-on-year sales increase to Rs 4,835.9 crore in the January-March period. This performance reinforces Sun Pharma's leading position in the Indian pharmaceutical market, with its market share growing to 8.4% from 8.1% a year ago. Sun Pharma enhanced its product range by launching 11 new products during the quarter and 37 for the entire fiscal year.
Innovative Medicines Show Strong Growth
Globally, the innovative medicines segment performed well, with sales rising 20.1% year-on-year to $354 million, making up 22.2% of the company's total consolidated revenue. In contrast, sales in the United States market saw a slight decrease of 1.1% to $459 million, as lower generic sales offset the gains from innovative products. The US market accounted for 28.8% of quarterly sales.
Financial Summary and Dividend
Consolidated revenue from operations grew by 13.6% year-on-year to Rs 14,559.8 crore for the quarter. Sun Pharma's board recommended a final dividend of Rs 5 per equity share. Combined with the interim dividend already distributed, the total dividend for FY26 remains at Rs 16 per share, consistent with the previous fiscal year.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) were Rs 3,954.2 crore, a 6.4% increase from the previous year, with an EBITDA margin of 27.1%. The company invested Rs 975.7 crore in research and development, representing 6.7% of sales. For the full fiscal year 2026, Sun Pharma recorded overall sales growth of 11.9%.